State Street Corp Sells 60,670 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

State Street Corp decreased its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 6.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 906,182 shares of the biotechnology company’s stock after selling 60,670 shares during the period. State Street Corp owned approximately 2.98% of AnaptysBio worth $30,357,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Ensign Peak Advisors Inc raised its holdings in AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 32,313 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in AnaptysBio by 202.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock worth $1,816,000 after acquiring an additional 36,300 shares during the last quarter. Victory Capital Management Inc. raised its holdings in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new stake in AnaptysBio during the 3rd quarter valued at $738,000.

AnaptysBio Trading Down 3.0 %

Shares of NASDAQ ANAB opened at $14.55 on Friday. AnaptysBio, Inc. has a 12-month low of $14.19 and a 12-month high of $41.31. The firm has a 50 day moving average of $23.87 and a 200 day moving average of $29.18. The firm has a market capitalization of $442.74 million, a price-to-earnings ratio of -2.39 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Sell-side analysts predict that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Insider Activity

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. The trade was a 8.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 33.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ANAB. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Wells Fargo & Company decreased their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday. HC Wainwright lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $52.00 to $19.00 in a research note on Wednesday, December 11th. Finally, Truist Financial decreased their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $41.45.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.